Evolutionary biology and CLL therapy
Results of Phase III POLLUX trial on daratumumab in multiple myeloma
How to explain the 'watch-and-wait' period to a CLL patient?
Why should young investigators join the CLL community?
Constantine Tam et al.
EBMT 2016 presentations overview: GvHD and metabolic syndrome